Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026)
Nexalin Technology's (NXL) quarterly Cash & Current Investments came in at $2.7 million in Q1 2026, up 32.05% year-on-year from $2.1 million in Q1 2025, and down 55.87% quarter-over-quarter from $6.1 million in Q4 2025.
Nexalin Technology (NXL) Cash & Current Investments (2021 - 2026) Analysis & Trends
Nexalin Technology's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 32.05% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 32.05% increase from a year earlier, with the FY2025 full-year figure at $6.1 million, up 76.35% from the prior year.
- Cash & Current Investments retreated to $2.7 million in Q1 2026 per NXL's latest filing, from $6.1 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $10.6 million in Q1 2023 and bottomed at $848796.0 in Q2 2024.
- The 5-year median for Cash & Current Investments is $5.8 million (2025), against an average of $5.5 million.
- Across the five-year window, Cash & Current Investments jumped 956.84% in 2022 and tumbled 90.49% in 2024, its largest moves.
- Year by year, Cash & Current Investments stood at $7.0 million in 2022, then tumbled by 57.84% to $2.9 million in 2023, then advanced by 18.03% to $3.5 million in 2024, then soared by 76.35% to $6.1 million in 2025, then plunged by 55.87% to $2.7 million in 2026.
- Per Business Quant, the three latest NXL Cash & Current Investments figures stand at $2.7 million (Q1 2026), $6.1 million (Q4 2025), and $4.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 7.30 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 9.22 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 3.67 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 1.12 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 2.29 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 577.00 Mn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 3.12 Bn |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 6.14 Mn |
| Sep 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 9.02 Mn |
| Jun 30, 2024 | 848,796.00 |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 7.15 Mn |
| Jun 30, 2023 | 8.93 Mn |
| Mar 31, 2023 | 10.60 Mn |
| Dec 31, 2022 | 6.99 Mn |
| Sep 30, 2022 | 7.86 Mn |
| Dec 31, 2021 | 661,778.00 |